

## Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross® has been advised by Glenmark Pharmaceuticals Canada Inc. that the shortage for GLN-Atovaquone 150 mg/mL oral suspension (DIN 02528495) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 15, 2023**. The following grouping was removed from the Critical Supply Product List **February 13, 2023**.

### ATOVAQUONE

#### 150 MG / ML ORAL SUSPENSION

00002528495	GLN-ATOVAQUONE	GLM	\$ 2.3785
00002217422	MEPRON	GSK	\$ 2.9456

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Tecnal capsule (DIN 00608238) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 13, 2023**. The following grouping was removed from the Critical Supply Product List **February 9, 2023**.

### BUTALBITAL / CAFFEINE / ASA

#### 50 MG / 40 MG / 330 MG CAPSULE

00000608238	TEVA-TECHNAL	TEV	\$ 1.5421
00000226327	FIORINAL	ARA	\$ 1.7168

Alberta Blue Cross has been advised by Sandoz Canada Inc. and Teva Canada Limited that the shortage for Sandoz Morphine SR 30 mg sustained-release tablet (DIN 02244791) and Teva-Morphine SR 30 mg sustained-release tablet (DIN 02302772) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 23, 2023**. The following grouping was removed from the Critical Supply Product List **February 21, 2023**.

### MORPHINE SULFATE

#### 30 MG SUSTAINED-RELEASE TABLET

00002244791	SANDOZ MORPHINE SR	SDZ	\$ 0.6580
00002302772	TEVA MORPHINE SR	TEV	\$ 0.6580
00002014297	MS CONTIN	PUR	\$ 1.1775

*continued next page*

continued from previous page

### Removal of temporary benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortages of Jamp-Quinine 300 mg capsule (DIN 02445204) manufactured by Jamp Pharma Corporation and Teva-Quinine 300 mg capsule (DIN 00021016) manufactured by Teva Canada Limited, Quinine-Odan 300 mg capsule (DIN 00695459) manufactured by Odan Laboratories Ltd. was added as a temporary benefit for the Alberta Drug Benefit List (ADBL).

Teva Canada Limited has advised Alberta Blue Cross that the shortage for Teva-Quinine 300 mg capsule (DIN 00695432) has been resolved.

**Quinine-Odan 300 mg capsule (DIN 00695459)** will no longer be considered a temporary benefit for the ADBL after **March 21, 2023**. The above grouping was removed from the Critical Supply Product List **February 17, 2023**.

Due to the shortages of Teva-Codeine 15 mg tablet (DIN 00593435) and Teva-Codeine 30 mg tablet (DIN 00593451) manufactured by Teva Canada Limited, Codeine Phosphate 5 mg/mL oral syrup (DIN 00050024) manufactured by Atlas Laboratories Inc. and Codeine 30 mg tablet (DIN 02009757) manufactured by Laboratoire Riva Inc. were added as temporary benefits for the Alberta Drug Benefit List (ADBL).

Teva Canada Limited has advised Alberta Blue Cross that the shortages for Teva-Codeine 15 mg tablet (DIN 00593435) and Teva-Codeine 30 mg tablet (DIN 00593451) have been resolved.

**Codeine Phosphate 5 mg/ml oral syrup (DIN 00050024)** and **Codeine 30 mg tablet (DIN 02009757)** will no longer be considered temporary benefits for the ADBL after **March 21, 2023**. The above grouping was removed from the Critical Supply Product List **February 17, 2023**.

Due to the shortages of Depo-Provera 150 mg/mL injection (DIN 00585092) and Depo-Provera 150 mg/mL prefilled syringe (DIN 02523493) manufactured by Pfizer Canada ULC, Depo-Provera 150 mg/mL injection (USA) (PIN 09858134) manufactured by Pfizer Canada ULC. was added as a temporary benefit for the Alberta Drug Benefit List (ADBL).

Pfizer Canada ULC has advised Alberta Blue Cross that the shortage for Depo-Provera 150 mg/mL prefilled syringe (DIN 02523493) has been resolved.

**Depo-Provera 150 mg/mL injection (USA) (PIN 09858134)** will no longer be considered a temporary benefit for the ADBL after **March 23, 2023**. The above grouping was removed from the Critical Supply Product List **February 23, 2023**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

